乳房X线摄影系统研发商ScreenPoint Medical获得1600万美元融资，引领乳腺癌护理领域人工智能的下一阶段发展-动脉网

ScreenPoint Medical Secures $16M to Lead the Next Phase of AI in Breast Cancer Care

PR Newswire 等信源发布 2026-04-17 22:00



可切换为仅中文







NIJMEGEN, Netherlands

荷兰奈梅亨

，

April 17, 2026

2026年4月17日

/PRNewswire/ -- ScreenPoint Medical, a leader in artificial intelligence solutions for breast cancer detection and risk assessment, today announced $14 million in new funding from existing investors, global software investor Insight Partners and Siemens Healthineers, in addition to $2 million in non-dilutive research grants..

/PRNewswire/ -- 乳腺癌检测和风险评估领域的人工智能解决方案领导者 ScreenPoint Medical 今天宣布，从现有投资者、全球软件投资者 Insight Partners 和西门子医疗集团获得了 1400 万美元的新资金，此外还获得了 200 万美元的非稀释性研究资助。

The investment reflects continued support from ScreenPoint Medical's long-term partners, commercial momentum within the United States and globally, and confidence in the company's vision of precision and personalised breast cancer care, from prevention and screening to treatment and beyond. Transpara® Breast AI solutions are deployed in 30+ countries with over 12 million mammograms processed to date, and they are used by many of the world's leading healthcare systems, screening programmes, universities, and imaging groups..

这项投资反映了ScreenPoint Medical长期合作伙伴的持续支持、美国及全球市场的商业动能，以及对公司从预防、筛查到治疗及其他方面实现精准和个性化乳腺癌护理愿景的信心。Transpara® Breast AI 解决方案已在30多个国家部署，迄今为止处理了超过1200万份乳腺X光片，并被许多世界领先的医疗系统、筛查项目、大学和影像机构使用。

This announcement also comes as the company's solutions have been the focus of groundbreaking new research this year:

这一公告发布之际，正值该公司解决方案成为今年突破性新研究的重点：

The first randomised controlled trial (RCT) in breast cancer AI (MASAI) published its final results

乳腺癌人工智能（MASAI）的首个随机对照试验（RCT）发布了最终结果。

[i]

on the use of Transpara in

关于Transpara的使用

The Lancet

柳叶刀

, finding 'consistently favourable outcomes compared with standard double reading' including significant impacts on cancer detection and workload reduction.

，发现“与标准的双重阅读相比，结果始终更有利”，包括对癌症检测和工作量减少的重大影响。

New prospective research

新的前瞻性研究

[ii]

on 'autonomous' AI published in

关于“自主”人工智能的出版物

Nature Medicine

自然医学

demonstrated that Transpara can safely reduce screening mammography workload by up to 63.6% by excluding low risk mammograms from radiologist readings.

证明了Transpara可以通过排除低风险的乳腺X光片免于放射科医生的阅读，从而安全地将筛查乳腺X光的工作量减少多达63.6%。

[iii]

在

npj Digital Medicine

npj 数字医学

，

[iv]

ScreenPoint Medical's image-based breast cancer risk algorithm

基于图像的乳腺癌风险算法——ScreenPoint Medical

[v]

outperformed other solutions (including Mirai, iCAD, and Google) at five-year risk prediction. Within the highest 14% of risk scores, the algorithm predicted 41.8% of all future cancers and 50.3% of interval cancers.

在五年风险预测中，优于其他解决方案（包括Mirai、iCAD和Google）。在最高14%的风险评分中，该算法预测了41.8%的所有未来癌症以及50.3%的间隔期癌症。

'This investment endorses our strategy and our shared success,' said Pieter Kroese, CEO of ScreenPoint Medical. 'We are well positioned to scale globally and accelerate the development of solutions that make care personal and powerful. Our goal is to support clinicians and women across the full continuum of breast cancer care.'.

“这项投资认可了我们的战略和我们共同的成功，”ScreenPoint Medical首席执行官皮特·克罗埃塞表示。“我们已经为全球扩展和加速开发个性化且高效的护理解决方案做好了充分准备。我们的目标是为整个乳腺癌护理过程中的临床医生和女性提供支持。”

'ScreenPoint Medical continues to lead and innovate in applying AI to breast imaging,' said Dr. Robert Epstein, MD, FACR, Health Care Senior Advisor at Insight Partners. 'The opportunity to create a greater level of personalised care is vast and clinically impactful at both a patient and population level.

“ScreenPoint Medical继续在将人工智能应用于乳腺成像方面引领创新，”Insight Partners的医疗保健高级顾问罗伯特·爱泼斯坦博士（医学博士、FACR）表示。“在患者和人群层面，创造更高水平个性化护理的机会是巨大的，并且具有临床影响力。”

We are excited to support ScreenPoint Medical as it builds an integrated and comprehensive approach.'.

我们很高兴支持 ScreenPoint Medical 构建一种综合且全面的方法。

This funding will support continued product innovation, international expansion, and strategic initiatives that strengthen ScreenPoint Medical's position as a trusted partner in the future of breast cancer care. Alexandra Krumbügel, Head of Product Line Women's Health, X-ray Products at Siemens Healthineers added: 'Our continued investment reflects our strong conviction that AI will play a defining role in the future of breast imaging.

这笔资金将支持持续的产品创新、国际扩张以及加强 ScreenPoint Medical 作为乳腺癌护理未来可信赖合作伙伴地位的战略举措。西门子医疗女性健康、X 射线产品线负责人亚历山德拉·克鲁姆比格尔补充道：“我们的持续投资反映了我们坚信人工智能将在乳腺成像的未来发挥决定性作用。”

This collaboration is driven by a shared focus on advancing breast cancer innovation and creating sustainable, long-term value for healthcare.'.

这种合作由共同致力于推进乳腺癌创新以及为医疗保健创造可持续的长期价值所驱动。

About ScreenPoint Medical

关于ScreenPoint Medical

In the fight against breast cancer, every image is an opportunity: to unlock insight, to uncover risk, to embody health, to empower life. We build AI-powered technology for every step of the breast imaging continuum, improving consistency, reducing uncertainty, enhancing patient experience, and translating opportunity into tangible outcomes..

在抗击乳腺癌的斗争中，每一张影像都是一个机会：获取洞察、揭示风险、体现健康、赋予生命力量。我们为乳腺影像连续体的每个步骤构建了人工智能技术，提高一致性、减少不确定性、改善患者体验，并将机会转化为切实的成果。

Proven through research, driven by innovation, and tailor-made for those seeking to lead in breast health, ScreenPoint's Transpara Breast AI is trusted by radiologists and women across the globe. We are Breast AI.

通过研究验证，创新驱动，并专为那些寻求在乳腺健康领域领先的人士量身定制，ScreenPoint的Transpara乳腺人工智能受到全球放射科医生和女性的信赖。我们就是乳腺人工智能。

Media Contact:

媒体联系人：

Cameron D Bowman

卡梅伦·D·鲍曼

[email protected]

电子邮件地址

References

参考文献

[i]

Gommers, et al. '

戈默斯等。

Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial

MASAI研究中，比较人工智能支持的乳腺X线摄影筛查与无AI的标准双阅片在间隔癌、敏感性和特异性方面的差异：一项随机、对照、非劣效性、单盲、基于人群的筛查准确性试验

The Lancet

柳叶刀

, 407, 505-514. January 2026.

，407，505-514。 2026年1月。

[ii]

Elías-Cabot, et al. '

埃利亚斯-卡博特等。

AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial

基于人工智能的乳腺X线摄影和数字断层合成在乳腺癌筛查中的分诊与决策支持：一项配对、非劣效性试验

Nature Medicine

自然医学

. March 2026.

. 2026年3月。

[iii]

Transpara is intended for use as a concurrent reading aid for physicians interpreting screening FFDM and DBT exams, to identify regions suspicious for breast cancer and assess their likelihood of malignancy. Any discussion of autonomous or rule-out applications represents future or investigational concepts and is not FDA-cleared or covered by the current CE certificate..

Transpara 旨在作为医生解读筛查 FFDM 和 DBT 检查的辅助工具，用于识别可疑乳腺癌的区域并评估其恶性可能性。任何关于自主或排除规则的应用讨论均属于未来或研究性概念，并未获得 FDA 批准，也不在当前 CE 证书的覆盖范围内。

[iv]

Rothwell, et al. '

罗斯威尔等人。

Performance of breast cancer risk prediction algorithms across mammography systems in the UK screening programme

英国筛查项目中乳腺癌风险预测算法在不同乳腺X线摄影系统中的表现

。'

npj Digital Medicine

npj 数字医学

. March 2026.

. 2026年3月。

[v]